Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cediranib + Cisplatin + Gemcitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cediranib | AZD-2171|Recentin|AZD2171|AZD 2171 | KIT Inhibitor 51 VEGFR1 Inhibitor 5 VEGFR2 Inhibitor 35 VEGFR3 Inhibitor 5 | Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778, PMID: 32444417). | |
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 6 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 12 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | lung non-small cell carcinoma | not applicable | Cediranib + Cisplatin + Gemcitabine | Phase I | Actionable | In a Phase I trial, the combination of Cediranib with Gemzar (gemcitabine) and Platinol (cisplatin) demonstrated preliminary efficacy in patients with advanced non-small cell lung cancer (PMID: 19091548). | 19091548 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|